Table of Contents Author Guidelines Submit a Manuscript
Advances in Orthopedics
Volume 2016, Article ID 3703482, 7 pages
Clinical Study

Effects of Zoledronate on Mortality and Morbidity after Surgical Treatment of Hip Fractures

1Department of Orthopedics and Traumatology, Faculty of Medicine, Bezmialem University, Fatih, 34050 Istanbul, Turkey
2Department of Orthopedics and Traumatology, Istanbul Faculty of Medicine, Istanbul University, Çapa Fatih, 34050 Istanbul, Turkey
3Muş State Hospital, Department of Orthopedics and Traumatology, 49100 Muş, Turkey
4Department of Orthopedics and Traumatology, Istanbul Medipol University, Bağcılar, 34214 Istanbul, Turkey

Received 7 December 2015; Revised 14 February 2016; Accepted 2 March 2016

Academic Editor: Robert F. Ostrum

Copyright © 2016 Ömer Cengiz et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


We aimed to evaluate the effects of intertrochanteric femoral fractures on mortality, morbidity, and cost of zoledronate treatment in elderly patients treated by osteosynthesis. Based on Evans classification, 114 patients with unstable intertrochanteric femoral fractures were treated with osteosynthesis. After the surgical treatment of intertrochanteric fractures, the treatment group (M/F, 24/32; mean age, 76.7 ± SD years) received zoledronate infusion, and the control group (M/F, 20/38; mean age, 80.2 ± SD years) received placebo. Postoperative control visits were performed at 6-week, 3-month, 6-month, and 12-month time points. Functional level of patients was evaluated by the modified Harris hip score and Merle d’Aubigné hip score. By 12 months, the mean HHS in treatment and control groups was 81.93 and 72.9, respectively. For time of death of the patients, mortality was found to be 57.1% (16/28) on the first 3 months and 92.9% (26/28) on the first six months. The mortality rate in the treatment and control groups was 14.3% (8/56) and 34.5% (20/58), respectively. The use of zoledronic acid after surgical treatment of intertrochanteric femoral fractures in osteoporotic elderly patients is a safe treatment modality which helps to reduce mortality, improves functional outcomes, and has less side effects with single dose use per year.